Beam Therapeutics Stock News

Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.

Beam Therapeutics Inc. (NASDAQ:BEAM)’s traded shares stood at 1.13 million during the last session. At the close of trading, the stock’s price was $64.60, to imply a decrease of -5.56% or -$3.8 in intraday trading. The BEAM share’s 52-week high remains $138.52, putting it -114.43% down since that peak but still an impressive 12.79% since … Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next? Read More »

These underappreciated opportunities in healthcare are worth a closer look.

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh

Its COVID pill is practically guaranteed to be the biggest story.

Pfizer gains access to Beam's gene-editing technology for three programs.

The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.

Pfizer gains access to Beam's gene-editing technology for three programs.

One is a rising star. The other might be more like a constellation.

The deal boosts Pfizer's internal mRNA development effort.

One is a rising star. The other might be more like a constellation.